FDA Approves New Option in Obesity
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
By
Kathryn Wighton
February 23, 2026
Clinical Scorecard: FDA Approves New Option in Obesity
At a Glance
Category Detail
Condition Obesity Key Mechanisms Swallowable gastric balloon promotes satiety and reduces caloric intake. Target Population Adults aged 22 to 65 years with obesity and at least one unsuccessful weight loss attempt. Care Setting Outpatient office visit.
Key Highlights
FDA approved Allurion Gastric Balloon System for obesity management. Device remains in stomach for approximately 4 months. Average residence time of 15.3 weeks before natural passage. Can be used in conjunction with lifestyle modification therapy. Up to two balloons permitted during a 10-month period. Guideline-Based Recommendations
Diagnosis
Assess body mass index (BMI) to confirm obesity diagnosis. Management
Use the Allurion Gastric Balloon System alongside moderate-intensity lifestyle modification. Monitoring & Follow-up
Monitor weight loss progress and adherence to lifestyle changes. Risks
Potential for adverse effects similar to glucagon-like peptide-1 receptor agonists. Patient & Prescribing Data
Estimated 80 million Americans with obesity within the indicated BMI range.
Device offers a non-surgical alternative to glucagon-like peptide-1s and bariatric surgery.
Clinical Best Practices
Incorporate lifestyle modification therapy with the gastric balloon treatment. Consider patient history of weight loss attempts before prescribing. References
